I) metaiodobenzylguanidine (MIBG) scanning was the only positive surveillance scan in 27% of patients and conclude that 123 I-MIBG scanning is the most reliable test for detection of clinically unsuspected tumor recurrence in this population. However, it is difficult to fully assess the reliability of 123 I-MIBG scanning based on the data provided for several reasons. The authors do not indicate how the diagnosis of recurrence was confirmed. This is a particularly important question for the 27% of patients who had no indication of relapse on any other form of imaging or surveillance. If there was no histopathologic confirmation of relapse, it may be possible that some patients had false positive The potential for a false-positive MIBG result has been described in a variety of clinical settings, including evaluation at diagnosis or relapse. Specific cases have been reported in an accessory spleen, 2 urinoma, 3 benign liver tumors, 4 and pyelonephritis. 5 Pfluger et al 5 quote a specificity of 85% for MIBG alone that increases to 95% when used in conjunction with magnetic resonance imaging in their study of 50 newly diagnosed patients. It therefore seems likely that some patients under post-treatment surveillance who develop MIBG changes only with no changes on computed tomography (CT) imaging will have false-positive scans.
To further address the specificity of 123 I-MIBG changes in the absence of CT changes we retrospectively evaluated the posttreatment surveillance at our institution over the last 10 years in a similar patient population to that described by Kushner et al. 1 Since 1999, our institution has had 13 patients with high-risk neuroblastoma who were treated with intensive induction therapy, autologous transplant, and radiation therapy 6 and achieved complete or very good partial remission status. During post-treatment surveillance imaging, five patients had positive 123 I-MIBG uptake with no evidence of evolving mass disease on concurrent CT. The patient details are described in Table 1 . One patient with focal 123 I-MIBG uptake in the liver (patient 2) had a biopsy performed that did not show any evidence of recurrent neuroblastoma. The remainder were followed with observation alone. All are currently alive with no evidence of disease at a median of 5 years follow-up (range, 7 to 100 months). One patient has long-term morbidity as a result of his treatment but no active NB disease. The remainder are well.
Our results suggest that when following high-risk neuroblastoma patients who are in complete or very good partial remission status, the presence of a positive MIBG scan in the absence of changes in other surveillance scans needs to be interpreted with caution. While three of the patients were between 12 and 18 
